环磷腺苷联合辅酶Q10在病毒性心肌炎患者临床治疗中的应用价值

doi:10.3760/cma.j.issn.1007-1245.2023.02.012

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (2): 195-.DOI: 10.3760/cma.j.issn.1007-1245.2023.02.012

环磷腺苷联合辅酶Q10在病毒性心肌炎患者临床治疗中的应用价值

董爱芝¹ 常以芳¹ 姜倩倩¹ 卢玲燕¹ 崔金珍¹ 李利娟¹ 范玉广¹ 冯泽瑞¹ 孙桂锋²

¹聊城市第二人民医院心内科三病区，聊城 252600；²聊城市东昌府人民医院心内科，聊城 252000

出版日期:2023-01-15 发布日期:2023-01-30
通讯作者: 孙桂锋，Email：sunguifeng2015@126.com
基金资助:
山东省中医药科技发展计划项目（2017-496）

Clinical value of cyclic adenosine monophosphate combined with coenzyme Q10 in the treatment of viral myocarditis

Dong Aizhi¹, Chang Yifang¹, Jiang Qianqian¹, Lu Lingyan¹, Cui Jinzhen¹, Li Lijuan¹, Fan Yuguang¹, Feng Zerui¹, Sun Guifeng²

¹Third Ward Division, Department of Cardiology, Liaocheng Second People's Hospital, Liaocheng 252600, China; ²Department of Cardiology, Liaocheng Dongchangfu People's Hospital, Liaocheng 252000, China

Online:2023-01-15 Published:2023-01-30
Contact: Sun Guifeng, Email: sunguifeng2015@126.com
Supported by:
Task Book of Project of Developmental Plan of Science and Technology of Traditional Chinese Medicine in Shandong (2017-496)

摘要/Abstract

摘要：

目的　探究环磷腺苷联合辅酶Q10应用于病毒性心肌炎患者临床治疗中的效果。方法　选取2020年4月至2022年4月在聊城市第二人民医院进行治疗的病毒性心肌炎患者95例为本次研究对象，采用电脑随机数字表法将其分为对照组与联合组。对照组48例，其中男27例，女21例，年龄20～50（35.21±7.04）岁；联合组47例，其中男22例，女25例，年龄为20～45（33.74±6.75）岁。对照组予以常规疗法加环磷腺苷治疗，联合组予以常规疗法加环磷腺苷和辅酶Q10治疗。比较两组患者的临床疗效、氧化应激指标水平、心肌损伤标志物水平及用药不良反应，采用t检验、χ²检验进行统计分析。结果　联合组有效率为97.87%（46/47），对照组为83.33%（40/48），两组比较，差异有统计学意义（P<0.05）。治疗后，两组超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）、过氧化氢酶（CAT）水平均高于治疗前，丙二醛（MDA）水平均低于治疗前（均P<0.05）；治疗后，联合组SOD为（84.31±12.04）IU/L、GSH-Px为（95.47±11.93）U/L、CAT为（75.43±8.38）U/L，均明显高于对照组［SOD为（78.65±11.24）IU/L、GSH-Px为（87.62±10.95）U/L、CAT为（67.21±7.47）U/L］，联合组MDA为（3.45±0.69）μmol/L，明显低于对照组［（4.37±0.87）μmol/L］，两组比较，差异均有统计学意义（P<0.05）。治疗后，两组C反应蛋白（CRP）、心肌肌钙蛋白I（cTnI）、肌酸激酶同工酶（CK-MB）、乳酸脱氢酶（LDH）水平均低于治疗前（均P<0.05）；治疗后，联合组CRP为（1.65±0.33）mg/L、cTnI为（0.31±0.07）μg/L、CK-MB为（12.37±2.47）U/L、LDH为（112.73±12.53）IU/L，均明显低于对照组［CRP（2.14±0.43）mg/L、cTnI（0.37±0.09）μg/L、CK-MB（15.41±3.08）U/L、LDH（142.84±15.87）IU/L］，两组比较，差异均有统计学意义（均P<0.05）。两组不良反应比较，差异无统计学意义（P>0.05）。结论　环磷腺苷联合辅酶Q10治疗病毒性心肌炎，能明显提高患者的临床疗效，改善氧化应激反应及心肌损伤，患者不良反应较少，安全可靠。

关键词:

病毒性心肌炎, 环磷腺苷, 辅酶Q10, 氧化应激, 心肌损伤

Abstract:

Objective　To explore the effect of cyclic adenosine monophosphate and coenzyme Q10 in the clinical treatment of patients with viral myocarditis. Methods　Ninety-five patients with viral myocarditis who were treated in Liaocheng Second People's Hospital from April 2020 to April 2022 were selected as the study objects. They were divided into a control group (48 cases) and a combination group (47 cases) by the computer random number table method. There were 27 males and 21 females in the control group who were 20-50 (35.21±7.04) years old. There were 22 males and 25 females in the combination group who were 20-45 (33.74±6.75) years old. The control group were treated with cyclic adenosine monophosphate and conventional therapy; and the combination group were treated with cyclic adenosine monophosphate, coenzyme Q10, and conventional therapy. The clinical efficacies, levels of oxidative stress indicators and myocardial injury markers, and adverse drug reactions of the two groups were compared and analyzed. t and χ² tests were applied. Results　The efficacy in the combination group was better than that in the control group [97.87% (46/47) vs. 83.33% (40/48)], with a statistical difference (P<0.05). After the treatment, the levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) were higher and the level of malondialdehyde (MDA) was lower than those before the treatment in both groups (all P<0.05). The levels of SOD, GSH-Px, CAT, and MDA in the combination group were better than those in the control group [(84.31±12.04) IU/L vs. (78.65±11.24) IU/L, (95.47±11.93) U/L vs. (87.62±10.95) IU/L, (75.43±8.38) U/L vs. (67.21±7.47) U/L, and (3.45±0.69) μmol/L vs. (4.37±0.87) μmol/L], with statistical differences (all P<0.05). After the treatment, the levels of C-reactive protein (CRP), cardiac troponin I (cTnI), creatine kinase isoenzyme (CK-MB), and lactate dehydrogenase (LDH) were lower than those before the treatment in both groups (all P<0.05). After the treatment, the levels of CRP, cTnI, CK-MB, and LDH in the combination group were significantly lower than those in the control group [(1.65±0.33) mg/L vs. (2.14±0.43) mg/L, (0.31±0.07) μg/L vs. (0.37±0.09) μg/L, (12.37±2.47) U/L vs. (15.41±3.08) U/L, and (112.73±12.53) IU/L vs. (142.84±15.87) IU/L], with statistical differences (all P<0.05). There was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions　The combination of cyclic adenosine monophosphate and coenzyme Q10 in the clinical treatment of patients with viral myocarditis can significantly improve the clinical efficacy, the oxidative stress reaction, and myocardial injury, and reduce the adverse reactions. It is safe and reliable.

Key words:

Viral myocarditis, Cyclic adenosine phosphate, Coenzyme Q10, Oxidative stress, Myocardial damage

董爱芝常以芳姜倩倩卢玲燕崔金珍李利娟范玉广冯泽瑞孙桂锋.

环磷腺苷联合辅酶Q10在病毒性心肌炎患者临床治疗中的应用价值 [J]. 国际医药卫生导报, 2023, 29(2): 195-.

Dong Aizhi, Chang Yifang, Jiang Qianqian, Lu Lingyan, Cui Jinzhen, Li Lijuan, Fan Yuguang, Feng Zerui, Sun Guifeng.

Clinical value of cyclic adenosine monophosphate combined with coenzyme Q10 in the treatment of viral myocarditis [J]. International Medicine and Health Guidance News, 2023, 29(2): 195-.

参考文献

[1] Wei H, Lin CK, Lu SJ, et al. CD11b is involved in coxsackievirus B3-induced viral myocarditis in mice by inducing Th17 cells[J]. Open Life Sci, 2020,15(1):1024-1032. DOI: 10.1515/biol-2020-0085.
[2] Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: from the influenza a to the COVID-19 pandemics[J]. Trends Cardiovasc Med, 2021,31(3):163-169. DOI: 10.1016/j.tcm.2020.12.007.
[3] Olejniczak M, Schwartz M, Webber E, et al. Viral myocarditis-incidence, diagnosis and management[J]. J Cardiothorac Vasc Anesth, 2020,34(6):1591-1601. DOI: 10.1053/j.jvca.2019.12.052.
[4] 王明亮,刘敏,徐亚伟,等.心肌缺血再灌注时内皮功能紊乱与心肌细胞凋亡的相关性研究[J].中华老年医学杂志,2021,40(4):501-505.DOI:10.3760/cma.j.issn.0254-9026. 2021.04.020.
[5] 李中豪,顾凯元,任晋宏.基于网络药理学和分子对接探讨黄芪治疗病毒性心肌炎的作用机制[J].天然产物研究与开发,2022,34(7):1223-1233,1212.DOI:10.16333/j. 1001-6880.2022.7.016.
[6] 王晨,李仁东,刘学兵,等.益心舒胶囊治疗病毒性心肌炎气阴两虚证的抗氧化、抗炎作用观察[J].中国实验方剂学杂志,2020,26(14):129-134.DOI:10.13422/j.cnki.syfjx.20200531.
[7] «中华心血管病杂志»编辑委员会心肌炎心肌病对策专题组.关于成人急性病毒性心肌炎诊断参考标准和采纳世界卫生组织及国际心脏病学会联合会工作组关于心肌病定义和分类的意见[J].中国循环杂志,2001,16(4):307-308.
[8] 谢淑芸,蒋靖波.左卡尼汀联合环磷腺苷对病毒性心肌炎患者的疗效及对IFN‐γ 和 IL‐4 水平的影响[J].心血管康复医学杂志,2019,28(4):478-481.DOI:10.3969/j.issn. 1008-0074. 2019.04.22.
[9] 王建,叶政,唐关敏.益脉养心汤在病毒性心肌炎治疗中的临床应用[J].中国中医药科技,2022,29(4):604-605.
[10] Gursu HA, Cetin II, Azak E, et al. The assessment of treatment outcomes in patients with acute viral myocarditis by speckle tracking and tissue Doppler methods[J]. Echocardiography, 2019,36(9):1666-1674. DOI: 10.1111/echo.14449.
[11] 崔福胜,王义文,张旭.参麦注射液对病毒性心肌炎患者血清细胞因子与心率变异性的影响观察[J].中国医学创新,2022,19(3):14-18.DOI:10.3969/j.issn.1674-4985. 2022.03.004.
[12] 李维天,黄悦.病毒性心肌炎患者应用益心舒片治疗效果观察[J].医学理论与实践,2022,35(5):766-767.DOI:10.19381/j.issn.1001-7585.2022.05.014.
[13] 康锐,王蒙,胡伟,等.环磷腺苷联合左卡尼汀治疗病毒性心肌炎的临床疗效评价[J].中国循证心血管医学杂志,2022,14(4):458-460.DOI:10.3969/j.issn.1674-4055. 2022.04.18.
[14] 张云燕,林威钢,杨晓鸿,等.磷酸肌酸钠联合辅酶Q10治疗病毒性心肌炎的效果[J].中国妇幼保健,2021,36(10):2265-2268.DOI:10.19829/j.zgfybj.issn. 1001-4411. 2021.10.023.
[15] 叶章正,林英娜,张晓丹,等.黄芪提取物对病毒性心肌炎大鼠心肌组织Nrf2、HO-1表达水平的影响[J].临床和实验医学杂志,2019,18(23):2483-2486.DOI:10.3969/j.issn. 1671-4695.2019.23.006.
[16] 朱建峰,李君,黄吕,等.心通颗粒对病毒性心肌炎小鼠炎症反应及心肌损伤的保护作用[J].中华医院感染学杂志,2021,31(21):3216-3220.DOI:10.11816/cn.ni. 2021-203565.
[17] Yin YJ, Zeng SL, Li YW, et al. The effect of coenzyme Q10 plus trimetazidine on acute viral myocarditis treatment[J]. Am J Transl Res, 2021,13(12):13854-13861.
[18] 郭宁,陈大兴,王杰,等.舒心通脉汤联合磷酸肌酸钠治疗病毒性心肌炎效果及对心肌功能指标的影响[J].中华中医药学刊,2020,38(5):190-193.DOI:10.13193/j.issn. 1673-7717. 2020.05.045.
[19] Calvo-Fernández A, Izquierdo A, Subirana I, et al. Markers of myocardial injury in the prediction of short-term COVID-19 prognosis[J]. Rev Esp Cardiol (Engl Ed), 2021,74(7):576-583. DOI: 10.1016/j.rec.2020.09.011.
[20] 朱小娟.环磷腺苷联合免疫球蛋白治疗病毒性心肌炎的治疗效果[J].内蒙古医学杂志,2020,52(7):800-801.DOI:10.16096/J.cnki.nmgyxzz.2020.52.07.014.
[21] 马瑞,郭祥富,彭松,等.参芍宁心饮加减联合辅酶Q10治疗病毒性心肌炎对患者HMGB1、MCP-1 的影响[J].四川中医,2021,39(5):66-69.

环磷腺苷联合辅酶Q10在病毒性心肌炎患者临床治疗中的应用价值

Clinical value of cyclic adenosine monophosphate combined with coenzyme Q10 in the treatment of viral myocarditis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

[1]	新吉夫, 乌仁图雅, 青格勒图. 近视儿童与青少年血清锌、铜、硒浓度的变化研究[J]. 国际医药卫生导报, 2022, 28(8): 1066-1069.
[2]	徐霞, 李振洁. Nrf2激活剂及其抗紫外线所致皮肤急性光损伤和慢性光老化的研究进展[J]. 国际医药卫生导报, 2022, 28(3): 303-307.
[3]	张娜刘梅嵇高德杨明鞠瀚. 2型糖尿病肾病患者血糖波动与肾功能和氧化应激的相关性分析[J]. 国际医药卫生导报, 2022, 28(23): 3296-.
[4]	王冰艳刘爱芬孙凤仙. 依托咪酯通过调控MAPK/ERK信号通路对阿尔茨海默病小鼠认知功能和氧化应激的影响[J]. 国际医药卫生导报, 2022, 28(22): 3118-3123.
[5]	李昕玺　刘长梅　祝慧　翟淼浡　商雪　赵嘉昊　徐会圃. 外泌体在心肌缺血再灌注损伤中作用的研究进展[J]. 国际医药卫生导报, 2022, 28(14): 1955-1958.